MRK Stock Chart & Fundamental Analysis

Fundamentals Charts

About MERCK & CO INC

Name

MERCK & CO INC

CEO

Robert Davis

Website

www.merck.com

Industry

Healthcare

Year Founded

1891

Employees

73,000

Merck & Co., Inc., listed on the NYSE under MRK, develops and markets human and animal health products as a global biopharmaceutical company. It operates in the drugmaking business, with FY2025 revenue of $64.9 billion, through a Pharmaceuticals segment focused on medicines and vaccines for people and an Animal Health segment serving veterinary care and livestock markets.

Analyst Ratings

Consensus Recommendation

Buy5

Hold1

Sell1

Fundamentals & Financials

Revenue (TTM)

$65.5B

Net Income (TTM)

$8.9B

EPS (TTM)

$3.56

ROA (TTM)

6.94%

Current Ratio

1.3

Dividend Yield

0.71%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q1 FY2026	Q4 FY2025	Q3 FY2025
Revenue	$16,286M	$16,324M	$17,183M
Cost of Sales	$2,944M	$4,817M	$4,194M
Gross Profit	$13,342M	$11,507M	$12,989M
Operating Income	-$1,884M	$6,160M	$7,463M
Net Income	-$4,240M	$2,963M	$5,785M
EPS	-$1.72	$1.2	$2.32

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

MERCK & CO INC's Technical Indicators Summary

Merck presents a broadly bullish setup with momentum and moving-average structure aligned to the upside. Short- and medium-term averages lie below the current price near 130 and the MACD and momentum metrics show constructive readings, while OBV supports buying interest and the pivot level sits below the market. Trend strength is moderate and stable, with ADX near the low-20s and volatility subdued at roughly a 2.6% ATR. Technical takeaway: broad moving-average support and positive momentum underpin a strong-buy stance, with trend strength steady but not extreme.

Buy

5 signals

Neutral

1 signal

Sell

1 signal

Overall: Bullish71% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	65.83	Neutral	RSI (65.83) is neutral.
Stochastic %K (14, 3, 3)	86.75	Sell	Stochastic (86.75) > 80, indicating overbought.
CCI (20)	127.48	Buy	CCI (127.48) > 100, indicating strong upward momentum.
WPR (14)	-3.90	Sell	Williams %R (-3.90) > -20, indicating overbought.
Momentum (10)	14.12	Buy	Momentum (14.12) is positive.
MFI	51.63	Neutral	MFI (51.63) is neutral.
MACD Level (12, 26)	3.05	Buy	Confirmed uptrend: MACD (3.05) is positive and above its signal line (1.98).
Bollinger Bands	$110.84 - $131.26	Neutral	Price is within the bands.
ATR (14)	$3.41 (2.63%)	Neutral	Moderate Volatility (2.63%).
ADX (14)	21.07	Neutral	Weak or consolidating trend (ADX < 25). ADX(21.07), +DI(33.41), -DI(18.08)
OBV	147,753,422	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(147,753,422), 20D-SMA-OBV(122,082,015)
Classic Pivot Point	$126.17	Buy	Price ($129.56) has broken above resistance R1 ($127.62) — bullish breakout potential.
Fibonacci Pivot Point	$126.17	Buy	Price ($129.56) has broken above resistance R1 ($127.58) — bullish breakout potential.
Simple Moving Averages	$107.23 - $123.65(5 indicators)	Buy	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.
Exponential Moving Averages	$106.10 - $124.87(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

MRK closed 3.31% above yesterday’s level of 125.37. Into the close, MRK still showed subdued interest, with volume at 0.40× its norm. MRK rises as investors focus on its pipeline and growth in oncology and vaccines, despite China-trials scrutiny.

Trading Volume

vs S&P 500 Today

Strong Outperformance

+4.48%

52-Week Position

Near highs

98.6%

Updated: July 2, 2026 at 20:10 UTC